Showing 2451-2460 of 3315 results for "".
- Topcon Healthcare Appoints Daniela Ferrara, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/topcon-healthcare-appoints-daniela-ferrara-md-phd-as-chief-medical-officer/2482764/Topcon Healthcare announced the appointment of Daniela Ferrara, MD, PhD, as its new Chief Medical Officer (CMO). In her new role, Dr. Ferrara will lead Topcon Healthcare’s global medical strategy, overseeing clinical r
- Medical Journals Cite “Harassment” After Increased Scrutiny from Justice Departmenthttps://modernod.com/news/medical-journals-cite-harassment-after-increased-scrutiny-from-justice-department/2482762/At least three major medical journals have reported receiving a letter from the U.S. Department of Justice (DOJ) that questioned their editorial practices and st
- CSI Dry Eye Software Announces Ken Barbet as New Chief Executive Officerhttps://modernod.com/news/csi-dry-eye-software-announces-ken-barbet-as-new-chief-executive-officer/2482754/Earlier this week, CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease management, announced Ken Barbet at the company’s new Chief Executive Officer (CEO). Mr. Barbet has 30 years of executive leade
- Johnson & Johnson to Present New Data for Tecnis Odyssey at ASCRShttps://modernod.com/news/johnson-johnson-to-present-new-data-for-tecnis-odyssey-at-ascrs/2482753/Johnson & Johnson will present data supporting the performance of the next-generation Tecnis Odyssey IOL at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles. J&J is featuring 22 company sponsored and investigator led studies
- Brent Saunders: Bausch + Lomb to Return enVista IOLs to Market Following Voluntary Recallhttps://modernod.com/news/bausch-lomb-returning-envista-iols-to-market-following-voluntary-recall/2482752/Bausch + Lomb announced it has identified the event that led to its recent
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Neurotech Appoints Beth Marsh as Chief Commercial Officerhttps://modernod.com/news/neurotech-appoints-beth-marsh-as-chief-commercial-officer/2482746/Neurotech Pharmaceuticals announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Ms. Marsh will lead the commercial organization, including preparing for the US launch of Encelto (revakinagene taroretcel-lwey), the first and onl
- Bausch + Lomb Recycles Over 625,000 Pounds of Eye Care Materialshttps://modernod.com/news/bausch-lomb-recycles-over-625000-pounds-of-eye-care-materials/2482745/Bausch + Lomb announced a sustainability milestone: its 'ONE by ONE' and 'Biotrue Eye Care' recycling programs have collectively diverted more than 103 million units, or 625,026 pounds, of used contact lenses and eye care materials fr
- Applications Being Accepted for the 2025 Ramin Tadayoni Awardhttps://modernod.com/news/applications-being-accepted-for-the-2025-ramin-tadayoni-award/2482740/Oculis, in collaboration with EURETINA, announced that applications are now being accepted for the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute
- Prevent Blindness Says West Virginia State House Bill Would Imperil Children’s Visionhttps://modernod.com/news/prevent-blindness-says-west-virginia-state-house-bill-would-imperil-childrens-vision/2482738/Prevent Blindness published a letter on its website Tuesday calling on the West Virginia State House to reject